A single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival benefit versus Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
The phase III EMERALD study found that when used as a monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer, elacestrant significantly improved progression-free survival in the overall population and in patients with tumors harboring estrogen receptor 1 mutations, compared to the standard of care.
CoImmune, Inc. and Memorial Sloan Kettering Cancer Center entered a license and collaboration agreement to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors.
Memorial Sloan Kettering Cancer Center researchers assessed patient satisfaction and preferences for telemedicine, finding that 45% of people with cancer preferred telemedicine, while 34% preferred office visits and 21% had no preference.
Researchers from Exscientia, the Medical University of Vienna, and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences demonstrated the impact of using Exscientia’s AI-supported precision medicine platform to propose which therapy would be most effective for late-stage hematological cancer patients, based on testing drug responses ex vivo in their own tissue samples.
Participants in a prospective, multi-center, randomized, crossover study (NILE – NCT04908254) reported significantly greater adherence to Dayspring treatment, an active compression treatment for lymphedema, in comparison to the use of pneumatic compression pump.
USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has launched a global registration, phase II clinical trial investigating the efficacy of a potential new breast cancer therapy called ARX788.
Ringling College of Art and Design and Moffitt Cancer Center will present an update on new developments from their collaborative INDEX Virtual Reality project to enhance the cancer patient experience and improve the accuracy of MRI-guided Radiation Therapy.
One in seven cancer patients around the world missed out on potentially life-saving operations during COVID-19 lockdowns, a study from the University of Birmingham in the U.K. found.
A study from USC Norris Comprehensive Cancer Center, part of Keck Medicine, showed that while cases of hepatocellular carcinoma have begun slowing in urban communities in the U.S., the incidence of the cancer is rising at a rate of 5.7% annually in rural areas, approaching urban rates.
